Mainz Biomed presented pivotal data from its largest cohort at the ASCO 2024 Annual Meeting through a poster presentation. This data consolidates findings from both the ColoFuture and eAArly DETECT studies, incorporating additional patients gathered since the initial study results. It underscores the significance of their innovative screening approach.

The combined analysis involved 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the United States. This encompassed previously unexamined and unreported samples, emphasizing the remarkable effectiveness of Mainz Biomed’s multimodal screening test. This test merges the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, supported by an advanced AI and machine learning algorithm. This amalgamation facilitates precise differentiation among colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas, and samples with no pathological findings.

Results from the poster session at ASCO 2024:

In May 2024, Mainz Biomed unveiled key findings from its groundbreaking eAArly DETECT study during a poster presentation at the renowned Digestive Disease Week (DDW) 2024 in Washington DC. The Digestive Disease Week judges awarded the company a Poster of Distinction.

KOL insights

“These results offer the unique promise of a self-administered screening tool with highly effective detection of adenomas (AA), a type of pre-cancerous polyp often attributed to this deadly disease” – Expert Opinion.

“Combining data from two studies is unusual, yet Mainz Biomed's consistent results reinforce the robustness of their test” – Expert Opinion.

“Mainz Biomed's 82% sensitivity for advanced adenomas blows Exact Sciences’ Cologuard's 43% out of the water” – Expert Opinion.

Conclusion

 

To conclude, this study underscored the substantial advantage of the multimodal screening test compared to existing methods, especially in identifying advanced precancerous lesions. Notably, the sensitivity for detecting high-grade dysplasia, which carries a heightened risk of progressing to cancer, with the multimodal approach was 95.8%, markedly surpassing other non-invasive tests presently accessible.